A pilot comparison study of four clinician‐rated atopic dermatitis severity scales

Male Adolescent 610 32 Biomedical and Clinical Sciences Dermatitis Dermatology anzsrc-for: 1103 Clinical Sciences Severity of Illness Index Atopic Dermatitis, Atopic 03 medical and health sciences anzsrc-for: 32 Biomedical and Clinical Sciences 0302 clinical medicine Humans Prospective Studies 3202 Clinical Sciences Observer Variation Eczema / Atopic Dermatitis anzsrc-for: 1112 Oncology and Carcinogenesis 3. Good health Quality of Life Feasibility Studies anzsrc-for: 3202 Clinical Sciences Female Self Report
DOI: 10.1111/bjd.13846 Publication Date: 2015-04-18T14:43:16Z
ABSTRACT
Background There are multiple severity outcome measures for atopic dermatitis (AD). is a need to compare the reliability of these measures. Objectives To inter-rater and intrarater objective Scoring Atopic Dermatitis (oSCORAD), Eczema Area Severity Index (EASI), Six Area, Sign (SASSAD) Three Item index (TIS); analyse correlation between quality-of-life instruments Patient-Orientated Measurement, Dermatology Life Quality Skindex-29. Methods Twelve patients with AD attended 1-day scoring exercise by five trained dermatology clinicians. Inter-rater were assessed using intraclass coefficient (ICC). Correlation clinician-rated patient-reported was analysed Spearman's rho. Results Regarding reliability, EASI SASSAD showed good reliabilities, ICCs 0·730 [95% confidence interval (CI) 0·500–0·900] 0·680 (95% CI 0·440–0·880), respectively. However, poor TIS oSCORAD, 0·497 0·233–0·785) 0·498 0·234–0·785), Separate body surface area (BSA) component analyses that oSCORAD BSA contributed its variations. excellent 0·886 0·744–0·952) 0·820 (0·614–0·923), respectively, while an ICC 0·720 0·424–0·878). 0·446 0·037–0·730). measures, only demonstrated moderate Skindex-29 (ρ = 0·611, P 0·035). Conclusions highest supporting it as optimal measure.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (35)
CITATIONS (34)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....